Nature Genetics🤖 AI summaryQuantitative Correlation Between Genetic Variants and Complex Binding Affinity Under Environmental Changes Revealed via Protein Fragment Complementation Assay
Background While advancements in genome sequencing have uncovered numerous genetic variants, determining the actual biochemical changes these variants cause within cells remains a difficult challenge. Previous genomic studies have primarily focused on changes in the expression levels of single proteins or whether protein structure collapses due to amino acid substitutions. A representative approach is the fragmented assessment of whether a variant causes loss-of-function in disease-associated variants. Cellular life processes are maintained not by the independent action of individual proteins, but by a complexly intertwined Protein-Protein Interaction (PPI) network. Most genetic variants tend to finely tune the binding affinity with specific partner proteins rather than completely destroying protein function. This has led to criticisms that it is difficult to identify the precise biological action of a variant without accurately measuring changes in binding strength at the complex interface. Environmental factors also add complexity to these interactions. Biological systems are constantly exposed to external stimuli such as nutrient depletion, heat shock, and osmotic stress. The same amino acid mutation can exhibit entirely different binding patterns depending on the physiological state. Due to technical limitations, large-scale studies tracking the quantitative impact of genetic variants on complex binding affinity under various environmental perturbation conditions have been rare. Key Findings Researchers analyzed the multidimensional network between genetic variants, environmental perturbations, and protein binding strength using the model eukaryote Saccharomyces cerevisiae. The Protein-fragment Complementation Assay (PCA) technique was used to measure binding strength. This molecular tool is designed so that when two proteins physically bind, split receptor fragments recombine to emit a signal. The researchers selected 61 protein pairs with already identified interactions and constructed a genotypic library encompassing both natural and artificial mutations. Subsequently, they calculated the quantitative changes in the binding strength of each protein pair under diverse environmental conditions, including increased incubation temperature, nutrient source switching, and treatment with chemical stress factors. The analysis results clearly demonstrate that the effects of genetic variants are not fixed. In many of the 61 binding pairs, the change in binding affinity due to mutations fluctuated sharply depending on the surrounding culture conditions. For instance, a specific metabolic protein variant, which showed a negligible difference in binding strength of less than 5% compared to the wild type in standard media, exhibited a non-linear response with a decrease in binding strength of over 40% under high-temperature stress conditions. Allosteric effects, where mutations located outside the protein binding interface disturb binding strength remotely when coupled with environmental stress, were also confirmed. This means that mutations classified as neutral by conventional structure prediction programs can act as factors that hinder complex formation in specific stress environments. Based on the collected binding dataset, the researchers succeeded in statistically classifying the proteins into a 'variable binding group' that responds sensitively to the environment and an 'invariant binding group' that maintains stable binding despite environmental changes. Significance and Outlook Moving beyond static genome sequence analysis to incorporate dynamic environmental variables into binding affinity expands the scope of systems biology research. This is because it demonstrates that when predicting the pathogenicity of variants in disease models, the physiological stress environment to which cells are exposed must be considered an essential input. It also shows potential as key training data for improving the accuracy of computer-based variant effect prediction algorithms. It provides a new analytical framework for the reclassification of Variants of Uncertain Significance (VUS), a major challenge in human genome analysis. This is because it cannot be ruled out that patient-derived variants may form abnormal bindings only within specific tissue-specific metabolic or inflammatory microenvironments. Expanding precision to the single-cell level and applying it to mammalian cell lines remain challenges to be addressed in the future. Further verification is required to see if the principles obtained from 61 protein pairs in budding yeast apply identically across the entire human interactome, which involves tens of thousands of intertwined proteins. The development of a next-generation quantitative screening platform capable of reflecting the diversity of post-translational modifications (PTM) in higher biological tissues is also identified as a subsequent challenge.
💡 Quantitative precision measurement techniques for protein complex binding strength according to mutations can be usefully integrated into the development processes of Proteolysis-Targeting Chimeras (PROTACs) or Molecular Glues. The efficiency of tertiary complex formation induced by compounds varies significantly depending on oxidative stress or hypoxic conditions in the tumor microenvironment. It can be utilized as a screening platform to early-screen for drug candidates that maintain appropriate binding affinity under patient-specific genetic variants and the physicochemical conditions of the lesion site. It is also expected to contribute to the establishment of customized combination therapy strategies by tracking the mechanisms of secondary mutations that induce anticancer drug resistance across different drug treatment environments.
Mini reviews in medicinal chemistry🤖 AI summaryFinding Clues for Healing Diabetic Chronic Ulcers by Regulating Macrophage Phenotype Switching
Background One in four diabetic patients experiences chronic wounds, such as diabetic foot ulcers, at least once in their lifetime. Most diabetes-related lower limb amputations stem from the worsening of these chronic ulcers. In a normal wound healing process, macrophages that drive the inflammatory response must timely transition into reparative macrophages that induce wound healing and tissue regeneration. In diabetic patients, the tissue environment disrupts this transition mechanism due to hyperglycemia and oxidative stress. As a result, pro-inflammatory M1 macrophages remain in the wound site for an excessively long period, and the transition to M2 macrophages, which promote regeneration, is delayed. This traps the wound site in a continuous cycle of inflammation. Since conventional simple disinfection or physical dressings make it difficult to fundamentally correct the immune imbalance within the microenvironment, a precise molecular targeted approach that directly regulates macrophage plasticity is urgently needed. Key Findings This review synthesizes the key signaling pathways and epigenetic regulatory axes that determine macrophage phenotypes during the diabetic wound healing process. The PI3K/AKT signaling pathway promotes M2 macrophage differentiation and cell survival, while the NF-κB pathway induces a strong inflammatory response, maintaining M1 activation. The Notch signaling pathway also controls the macrophage differentiation trajectory, determining the balance between tissue repair and persistent inflammation. At the epigenetic level, DNA methyltransferases (DNMT), histone-modifying enzymes, and non-coding RNAs (ncRNA) act as key factors that turn M1 or M2 transcriptional programs on and off. Based on these pathophysiological mechanisms, natural active substances such as emodin and Astragalus Polysaccharides (APS) are gaining attention. These components have shown effects in inducing M2 polarization by suppressing oxidative stress at the wound site and regulating signaling pathways. In terms of targeted delivery technology, immunomodulatory hydrogels, extracellular vesicles (EVs), and gene-targeted nanoparticles are being reviewed as candidate materials to deliver cell reprogramming factors directly to the lesion. However, due to the complexity of the in vivo wound microenvironment, macrophage phenotypes fluctuate unpredictably, and the lack of highly reliable delivery platforms that selectively target only wound-site macrophages remains a major obstacle. Significance and Outlook A therapeutic strategy targeting macrophage plasticity provides an opportunity to shift the treatment paradigm for diabetic chronic ulcers from inflammation suppression to the reconstruction of the immune microenvironment. If convergence technologies are established to load epigenetic regulatory substances or gene-editing tools into biomaterial-based carriers, they hold the potential to restore damaged immune homeostasis and dramatically accelerate tissue regeneration. However, the significant difference between animal models and the actual in vivo wound environment of diabetic patients is a barrier that must be overcome. Along with the development of intelligent release-controlled platforms capable of responding to the variability of the local microenvironment, establishing precise administration strategies tailored to the wound progression stage of each patient remains a key task for follow-up research.
💡 This research provides a clear benchmark for shifting the development of dressing agents in the treatment of diabetic foot ulcers from material protection to active immune regulation. In clinical settings, a combined treatment protocol can be implemented by immediately applying M2 polarization-inducing hydrogels after surgical debridement to early prevent entrapment in chronic inflammation. In the pharmaceutical and biomaterials industries, it is possible to commercialize functional smart patches that release proven safe components like Astragalus Polysaccharides or emodin, or to expand into the development of customized topical treatments using patient-derived extracellular vesicles. It is expected to contribute to improving patient quality of life and reducing the massive burden of medical costs by substantially shortening the treatment period for chronic ulcers and lowering the rate of lower limb amputation.
Critical reviews in oncology/hematology🤖 AI summaryEvolution of CRISPR Genome Editing and Next-Generation Delivery Technologies to Overcome Refractoriness in Prostate Cancer Treatment
Background Prostate cancer, a leading cause of cancer-related death in men, is a difficult-to-treat intractable disease due to high molecular heterogeneity within tumor tissues. Current clinical practice primarily relies on Androgen Deprivation Therapy (ADT) and targeted anticancer drugs. While most patients respond to initial treatment, they eventually develop drug resistance, progressing to Castration-Resistant Prostate Cancer (CRPC). There is an urgent need for personalized therapeutic strategies that can accurately identify and reverse the molecular mechanisms of tumor resistance to treatment. Existing approaches based on gene knockdown or small molecule compounds have faced limitations, such as frequent off-target effects and the inability to fundamentally correct genomic structures. The emergence of molecular tools capable of precisely correcting complex genetic mutations and epigenetic abnormalities has become a top priority in prostate cancer research. Key Findings In the field of prostate cancer, genome editing technology is evolving beyond simple cleavage enzymes into precision correction tools. Following the advent of third-generation gene scissors, such as CRISPR-Cas9 nucleases, there is a growing trend to actively incorporate Base Editing, which substitutes single bases without inducing DNA double-strand breaks, and Prime Editing, which induces insertions and deletions by combining reverse transcriptase, into research models. CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) systems, which finely regulate gene expression, are also widely used to identify prostate cancer gene functions. Researchers identify Androgen Receptor (AR) signaling and DNA Damage Repair (DDR) systems as key molecular pathways driving prostate cancer progression. In particular, loss of the tumor suppressor gene PTEN and the TMPRSS2-ERG fusion gene, a prostate cancer-specific genetic mutation, are decisive factors in disease progression and treatment response. Functional Genomic Screening techniques have achieved success in large-scale identification of synthetic lethality targets that induce selective death only in cancer cells possessing these genetic deficiencies. Multifaceted therapeutic strategies to overcome drug resistance have also been reported. These include methods such as targeting mutation sites in the AR signaling pathway to neutralize resistance to next-generation androgen receptor inhibitors, or correcting DDR gene mutations to restore sensitivity to radiation and chemotherapy. Epigenome editing technology, which reprograms epigenetic marks, and cell therapy engineering technology, which enhances tumor-killing capabilities by manipulating patient immune cells, are also considered new alternatives. Research on delivery vehicles to implement therapeutic efficacy in vivo is also advancing rapidly. In addition to viral vectors such as Adeno-Associated Virus (AAV), lipid nanoparticles (LNP) that minimize in vivo immune responses, biodegradable polymer carriers, and extracellular vesicles (EV) are being evaluated as delivery vehicles specific to prostate tumors. Significance and Outlook The advancement of CRISPR genome editing tools has provided a turning point, shifting the paradigm of prostate cancer treatment from symptom relief to the correction of causative genes. This is made possible by the implementation of precision oncology, which designs synthetic lethal drug combinations and preemptively blocks resistance mechanisms based on patient genomic information. However, barriers to overcome still exist. It is pointed out that challenges to be addressed include the risk of genomic toxicity due to in vivo off-target effects, immunogenic reactions that may occur upon repeated administration, and the issue of delivery efficiency in achieving uniform penetration of the correction agent into deep tumor regions. The development of next-generation targeting technologies to overcome the fibrotic microenvironment and high cellular heterogeneity unique to prostate cancer tissue is expected to be the deciding factor for commercialization.
💡 This research provides a specific preclinical development roadmap for solving the recurring problem of drug refractoriness in patients with castration-resistant prostate cancer. Pharmaceutical and biotech companies can rapidly design new small molecule compounds or antibody-drug conjugates (ADCs) based on synthetic lethality candidates discovered through large-scale CRISPR screening. In the clinical stage, promising commercialization scenarios include the direct administration of LNP-based CRISPR therapeutics tailored to genetic mutations in patient biopsy tissues, or the generation of allogeneic CAR-T cells with knocked-out immune checkpoint receptors as part of a combination therapy strategy designed to penetrate the solid tumor microenvironment.
Molecular and cellular endocrinology🤖 AI summaryBeyond M1/M2 Dichotomy: Macrophage Immunometabolism Identified as Mechanism for Sequential Damage in Heart, Liver, and Kidney Complex Diseases
Background As the prevalence of obesity and type 2 diabetes surges, there is an increasing number of patients with complex metabolic diseases characterized by simultaneous dysfunction of the heart, liver, and kidneys. In clinical practice, cases where Cardiovascular-Kidney-Metabolic (CKM) syndrome or metabolic dysfunction-associated steatohepatitis (MASH) rapidly progress to heart failure or end-stage renal disease are frequently observed. A notable point is that the simultaneous damage to these three organs is not a simple complication resulting from independent occurrences. The traditional medical establishment has strictly divided specialties such as cardiology, hepatology, and nephrology, primarily tracking local lesions of each organ. Therapies targeting specific organs have been insufficient to block the spread of inflammation that triggers chain reactions in other organs. While chronic low-grade inflammation has been identified as the fundamental cause, the identity of the immunological mediators spreading inflammation across organs has long remained veiled. This is why there has been a persistent call to elucidate the cross-talk pathways of immune-metabolic signals exchanged among the three organs. Key Findings Researchers have identified macrophages as the key mediators driving tissue damage and interaction among the three metabolic organs—heart, liver, and kidney—and have comprehensively summarized the pathological mechanism from an immunometabolic perspective. The existing binary classification system that simply divides tissue macrophages into pro-inflammatory M1 and anti-inflammatory M2 is considered unable to fully capture the actual in vivo heterogeneity. In metabolic disease lesions, glucolipotoxicity—the combination of hyperglycemia and dyslipidemia—directly disrupts the intracellular metabolic pathways of macrophages. When macrophages are exposed to excessive glucose and free fatty acids, the intracellular Sirtuin (SIRT) signaling pathway is inhibited, while abnormal hyperactivation of the NOD-like receptor protein 3 (NLRP3) inflammasome in the cytoplasm is induced. This metabolic imbalance promotes metabolic reprogramming that disrupts macrophage mitochondrial respiration, shifting them toward a pro-inflammatory phenotype. A macrophage subpopulation expressing chemokine receptor 2 (CCR2) is cited as the central axis mediating the vicious cycle between organs. CCR2-positive macrophages, activated by inflammatory stimuli in liver lesions, released large amounts of cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) into the bloodstream. The released cytokines travel through the blood vessels to infiltrate myocardial and renal tissues, stimulating local capillary endothelial cells and promoting infiltration. In cardiomyocytes, fibrosis and impaired relaxation functions follow, while in renal glomeruli, podocyte damage and proteinuria are triggered. The analysis suggests that the three organs do not fail independently, but rather undergo a simultaneous collapse in a networked manner due to signals transmitted by the immunometabolic reprogramming of macrophages. Significance and Outlook This analysis heralds a paradigm shift from the existing approach of treating the heart, liver, and kidney as individual disease units. As the dysregulation of macrophage immunometabolism has emerged as a common pathological engine for the three organs, a foothold has been established for discovering common targets capable of simultaneously controlling multi-organ damage. Multi-target strategies, such as using SIRT activators, NLRP3 inflammasome inhibitors, or CCR2 antagonists to break the inter-organ inflammatory chain, are cited as representative alternatives. Challenges to clinical application remain significant. Macrophages in vivo naturally perform their inherent physiological functions of defending against infection and repairing damaged tissue. If pathogenic macrophage subpopulations cannot be selectively inhibited, there is a persistent risk of side effects such as systemic immune suppression or delayed tissue regeneration. It is time for the co-development of precision delivery technologies that can identify unique markers of target subpopulations by integrating single-cell transcriptomics and spatial biology techniques, and deliver drugs specifically to those cells.
💡 This research provides a concrete direction for the development of next-generation metabolic disease drugs and the design of clinical trials. Moving away from the existing practice of independently developing treatments for liver disease or heart failure, establishing a multi-organ combination drug pipeline that simultaneously targets inhibition of liver fibrosis and preservation of cardiac and renal function by regulating the macrophage SIRT/NLRP3 axis is emerging as a realistic alternative. The potential for application in the clinical diagnostic field is also high. By tracking circulating CCR2-positive monocyte levels or macrophage-specific metabolic markers carried in exosomes using liquid biopsy technology, a customized monitoring system can be established to early identify high-risk groups among patients with metabolic disorders who are likely to develop fatal multi-organ complications such as myocardial infarction or chronic renal failure.
Hepatology communications🤖 AI summaryMechanism of MTARC1 Gene Variant Protecting Against Fatty Liver Fibrosis Revealed via Liver Organoids and Prime Editing
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a representative chronic liver disease affecting approximately 30% of the global population. It is a multifactorial disease that begins with simple fat accumulation in hepatocytes and progresses to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and eventually liver cancer. The patterns of onset and progression are strongly influenced by individual genetic factors. Genome-wide association studies (GWAS) have reported various single-nucleotide polymorphisms (SNPs) that increase or decrease disease risk. The rs2642438 (p.A165T) variant of the Mitochondrial amidoxime reducing component 1 (MTARC1) gene has been identified as a protective factor that significantly reduces the risk of fatty liver and cirrhosis in patient cohorts. While the epidemiological link between the genotype and disease suppression was confirmed, it remained unclear what metabolic mechanism MTARC1 employs within hepatocytes and how a single variant alters cellular phenotypes. This was due to the difficulty of proving pure causality of a single variant using patient-derived cells with diverse genomic backgrounds or simple 2D in vitro culture models. Key Findings Researchers solved this problem by combining prime editing, a next-generation gene editing technology, with a 3D organoid culture system. Using prime editors at the human embryonic stem cell (hESC) stage, they precisely introduced the MTARC1 rs2642438 variant and then differentiated them into human liver organoids (HLOs). This allowed for a comparative experiment design where control organoids maintaining the reference sequence and organoids possessing only the single nucleotide variant were produced side-by-side within the same genomic background. When free fatty acids and inflammatory stimuli were applied to the differentiated HLOs to induce fat accumulation and fibrotic damage, clear phenotypic differences emerged. HLOs with the rs2642438 variant showed significantly lower MTARC1 protein expression and a substantial reduction in intracellular triglyceride accumulation compared to reference sequence HLOs. They also exhibited a distinct pattern of protection from fatty liver lesions and fibrotic responses even under lipotoxicity and inflammatory stimuli. The disease-suppressing effects observed in the patient cohort were successfully reproduced in a 3D human tissue model. Tracing the mechanism of triglyceride reduction revealed that the primary driver was the direct inhibition of the intracellular de novo lipogenesis (DNL) pathway, rather than the promotion of mitochondrial β-oxidation. As the amount of MTARC1 protein decreased, the metabolic signals inducing fatty acid synthesis were blocked. Interesting data were also obtained from drug response evaluations. When resmetirom, an FDA-approved thyroid hormone receptor-beta (THRB) agonist, was administered, triglyceride levels significantly decreased in the reference sequence HLOs under fatty liver injury conditions. Conversely, in HLOs already possessing the rs2642438 protective variant, triglyceride levels did not decrease further upon additional treatment with resmetirom. This is interpreted as the drug's action being redundant, as the protective variant itself already substantially blocks the fat accumulation pathway. Significance and Outlook This study demonstrates that stem cell-derived organoids generated via prime editing serve as a powerful preclinical platform for establishing the causality of disease-associated genetic variants. It is noted that this approach confirmed at the molecular level how minute genetic differences at the single-nucleotide level induce disease resistance in human tissue models. These findings strongly support the potential of MTARC1 inhibitors as promising new drug targets from a therapeutic strategy perspective. There is growing expectation that antisense oligonucleotides (ASOs) or small-molecule compounds that artificially suppress MTARC1 expression or function may confer liver-protective effects similar to those observed with genetic protective variants. The resmetirom responsiveness data highlights the need for patient-specific precision medicine. This is because for MASH patients carrying specific protective variants, the expected effect of resmetirom treatment may be limited. In future clinical trial designs for new drugs, stratified analysis according to the patient's MTAR1 genotype is likely to serve as a crucial variable. A challenge to overcome is that stem cell-derived liver organoids may not fully reflect the immune cell interactions or microvascular environments of actual adult liver tissue. Subsequent verification using immune cell co-culture systems or liver microfluidic chip-based models will be necessary to evaluate their impact on long-term in vivo metabolic homeostasis.
💡 This research provides a direct standard for establishing patient-specific treatment strategies in the development of MASH therapeutics. By pre-screening for the presence of the MTARC1 rs2642438 genotype, the priority of administering specific mechanism-based therapies such as resmetirom can be adjusted, or patient groups with a high probability of response can be selected. Meanwhile, the pharmaceutical and biotechnology industry has gained momentum to accelerate the development of MTARC1 inhibitors as a new target for controlling lipid accumulation in hepatocytes. Designing gene therapy pipelines that use siRNA or ASO to lower MTARC1 protein levels in hepatocytes is emerging as a promising alternative.
PNAS🤖 AI summaryDifferences in Light Response of Drosophila Circadian Neurons Revealed by Single-Nucleus Transcriptomic Map
Background Light is the most powerful environmental signal for entraining the biological clock to external day and night. The central brain of adult Drosophila contains approximately 240 circadian neurons, with over 25 subtypes identified through connectome analysis. While this small number of cells regulates sleep, wakefulness, and activity timing, the specific genes expressed by each neuron throughout the day and their responses to light have not been sufficiently resolved. Existing single-cell RNA sequencing faced difficulties in distinguishing technical batch effects from actual circadian changes because samples from different time points were processed separately. There was also the issue of losing large, fragile neurosecretory neurons during the cell dissociation process. Specifically, large ventral lateral neurons (l-LNv) and some dorsal lateral neurons (LNd) were underrepresented compared to their actual abundance in the brain. Consequently, there remained limitations in separating transcription directly induced by light from the rhythms generated by the internal cellular clock. Key Findings Researchers at Brandeis University optimized EL-INTACT, which isolates labeled nuclei from frozen Drosophila heads, for single-nucleus RNA sequencing (snRNA-seq). Here, single nucleotide polymorphisms from the Drosophila Genetic Reference Panel (DGRP) were used as sample barcodes. This design reduces batch effects in 10x Genomics experiments by processing nuclei from different time zones together and using genotypes to trace back the original conditions. The researchers investigated 12 time points at 2-hour intervals under both light-dark cycles and constant darkness. In the light-dark cycle, 9,899 circadian neuron nuclei were obtained, and 9,835 were obtained on the second day of constant darkness; both datasets were classified into 24 transcriptomic clusters. Rare neurosecretory neurons, including l-LNv, which was nearly missing in previous analyses, were recovered. This significantly increased the sample density for detecting time-dependent changes. In several neuron types, the same cell groups clearly diverged depending on the collection time, and numerous transcripts, including core clock genes timeless and Pdp1, oscillated even in constant darkness. This provides evidence that most observed changes stem from intrinsic circadian transcriptional regulation rather than simple light-dark transitions. The researchers applied the JTK_cycle algorithm to determine 24-hour rhythms per gene, using strict criteria reflecting maximum expression and amplitudes of more than twofold. Transcripts dependent solely on light were fewer than expected. However, Hr38 and stripe (sr), which correspond to immediate-early genes in mammals, showed short, intense bursts of expression in LNv at the onset of light. No signal was detected 2 hours before or after light onset, nor under constant darkness conditions at the same time. Additional analysis at 15, 30, and 60 minutes after light onset supported that this response is a transient transcriptional wave rather than a sustained increase. A key finding was that not all circadian neurons respond in the same manner. Significance and Outlook This study demonstrates that the Drosophila brain's biological clock is not a uniform oscillator but a network where each neuron type possesses its own transcriptional rhythm and light response. In particular, it suggests that external light may adjust the internal clock by transiently activating activity-dependent genes like Hr38 and sr in specific neurons, rather than uniformly altering widespread gene expression. This reaction is a candidate molecular link for circadian entrainment or phase shifts. The multiplexing of EL-INTACT and DGRP is significant as it allows for the analysis of time-series transcriptomes of rare cells with minimized batch effects. The use of frozen samples facilitates the collection of various conditions and time points in advance, allowing them to be processed together. However, it cannot be concluded from temporal correlations of transcripts alone that Hr38 and sr are the causes of behavioral phase regulation. The causal roles of each neuron must be confirmed by combining gene-specific functional inhibition, neural activity measurement, and behavioral rhythm analysis. Whether the cell-type-specific responses observed in Drosophila are conserved in the mammalian suprachiasmatic nucleus remains a follow-up task.
💡 This map can be utilized to narrow down cellular targets for evaluating the effects of light stimulation in research on sleep, shift work, and jet lag. For example, by measuring the shift in Hr38 or sr expression and activity rhythms after providing light at a specific time, one can distinguish between neurons that reset the biological clock and those that simply detect light. In pharmaceutical research, researchers can explore candidate mechanisms for shifting phase without light exposure by screening compounds that regulate the upstream signals or receptors of these genes. Industrially, there is potential to expand this into a time-series screening platform that combines rare cell analysis based on frozen tissue with genotypic multiplexing. However, since the human circadian circuit is more complex than that of Drosophila and light input pathways differ, translating these results into treatment strategies for sleep disorders requires prior replication in mammalian models and clinical samples.
Frontiers in immunology🤖 AI summaryNew therapeutic strategy to control fatal secondary brain injury following intracerebral hemorrhage via cell-specific epigenetic switches
Background Intracerebral hemorrhage (ICH) is a severe condition with the highest case fatality rate and risk of long-term disability among all types of stroke. While the physical compression from hematomas caused by vascular rupture is dangerous, secondary brain injury that expands rapidly from hours to days after the bleed is the decisive factor determining patient prognosis. When bleeding occurs, red blood cells within the hematoma break down, releasing large amounts of hemoglobin degradation products and iron. The oxidative stress and damage-associated molecular patterns (DAMPs) induced by these substances often create a harmful inflammatory microenvironment within the brain. This triggers a neuroinflammatory cascade that destroys surrounding neurons and rapidly exacerbates cerebral edema. The academic community has focused on developing classical drugs to block inflammatory cytokines or remove reactive oxygen species. However, analyses suggest that single-target therapies have failed in clinical trials because they could not control the complex immune response, due to the failure to uncover the precise molecular mechanisms governing the onset, progression, and normal resolution of inflammation. Key Findings A neurology research team from the First Hospital of Jilin University, China, demonstrated in a paper published in the international journal 'Frontiers in Immunology' that epigenetic regulation is a key axis controlling secondary injury in ICH. They explained that stimuli from the hemorrhage microenvironment cause 'immuno-epigenetic remodeling,' which reshapes gene expression patterns without changing the base sequence. According to the researchers, hematoma degradation products and iron overload trigger a cascade involving DNA methylation, histone modification, chromatin accessibility, and non-coding RNA (ncRNA) regulatory networks. This mechanism induces cell-type-specific transcriptional reprogramming across microglia, astrocytes, endothelial cells, and infiltrating leukocytes. In the past, these epigenetic modifications were dismissed as mere byproducts of damage. Conversely, the research team identified that epigenetic mechanisms actively govern innate immune activation, cytokine secretion, leukocyte recruitment, and the preservation of the blood-brain barrier (BBB). They pointed out that the reason microglia in the early stages of injury remain trapped in a harmful neurotoxic state and fail to transition to a restorative state lies in irreversible epigenetic modifications. The molecular pathways through which endothelial dysfunction and maladaptive inflammatory memory become chronic are also explained in this context. Significance and Outlook This study is recognized for shifting the strategy for addressing secondary brain injury from simple inflammation suppression to 'cell-specific epigenetic regulation.' It paves the way for designing precision immunotherapies that block harmful inflammatory pathways while promoting tissue repair, rather than relying on indiscriminate systemic immune suppression. The research team identified 'locus-specific epigenome editing' technology, which targets only specific gene regions, and customized, stage-specific ncRNA therapeutics as promising alternatives. Strategies to target the optimal therapeutic window by tracking the rapidly changing epigenetic dynamics of immune cells from the moment of hemorrhage are also becoming visible. Practical barriers to commercialization remain significant. The risk of off-target effects of epigenetic drugs on the systemic immune system must be minimized. Therefore, developing a precision drug delivery system (DDS) that delivers drugs only to the damaged brain areas and specific immune cells is a crucial task. Subsequent preclinical studies should follow to verify the impact of resetting modified immune memory on normal neural network function.
💡 This study provides specific guidelines for the development of customized neuroprotective agents for patients with refractory intracerebral hemorrhage. Currently, in clinical settings, there are no drug therapies available to prevent secondary brain injury other than acute-phase hematoma removal surgery. The biopharmaceutical industry can explore drug repositioning strategies, such as repurposing histone deacetylase (HDAC) inhibitors or DNA methyltransferase (DNMT) regulatory compounds for acute ICH treatment, based on the systematized cell-specific epigenetic targets identified here. Furthermore, clinical scenarios combining antisense oligonucleotides (ASOs) or lipid nanoparticle (LNP)-based mRNA delivery technologies that block the entrapment of microglia in a harmful inflammatory state with emergency protocols for acute brain diseases are expected to become a reality. This is considered a practical therapeutic alternative that can significantly reduce cerebral edema complications in ICU patients with intracerebral hemorrhage and decrease permanent neurological disability, thereby facilitating an early return to normal daily activities.
Neuro-oncology advances🤖 AI summaryIdentification of XPO1 as a Key Molecular Vulnerability in Pediatric Atypical Teratoid/Rhabdoid Tumor (ATRT) and the Effect of Selective Nuclear Export Inhibition
Background Atypical Teratoid/Rhabdoid Tumor (ATRT) is a fatal malignant brain tumor primarily occurring in infants under 3 years of age. The disease progresses rapidly, with an average survival period of only about one year after diagnosis. Current treatments involving high-dose chemotherapy or radiation pose risks of irreversible side effects such as brain damage and developmental delays in growing pediatric patients. Even if patients endure the harsh treatment, tumors recur easily, keeping long-term survival rates at the lowest levels. The failure of conventional anticancer treatments stems from the disease's unique genetic defects. Instead of the complex mutations common in adult cancers, ATRT cells share a common denominator: the loss of the tumor suppressor gene SMARCB1. Given that the disease is triggered by the loss of a single tumor suppressor, it is considered extremely difficult to artificially restore the function of the already lost protein. Due to the absence of targeted therapies, clinical practice has relied on high-dose regimens with significant risks. To overcome these limitations, it is essential to identify alternative molecular targets—genetic dependencies—that cancer cells rely on for survival. There was an urgent need to explore molecular bypasses that could precisely strike cancer cells while minimizing damage to normal cells. Key Findings The research team embarked on a multifaceted validation combining patient-derived ATRT cell lines, functional genomics technologies, drug screening, and transcriptome analysis. Comparative analysis of pediatric brain tumor transcriptome big data against controls revealed interesting differences. Compared with other pediatric brain tumor cell lines, ATRT cells exhibited overwhelmingly higher expression levels of the nuclear export protein Exportin-1 (XPO1). XPO1 functions as a channel that transports tumor suppressor proteins from inside the nucleus to the cytoplasm, thereby inducing their degradation. Functional verification followed to see if ATRT cells actually depend on XPO1 for survival. When XPO1 expression was blocked using CRISPR/Cas9 gene-editing technology, cancer cell proliferation immediately halted. Similarly, administering six types of Selective Inhibitors of Nuclear Export (SINE) compounds to patient-derived cancer cells resulted in a sharp drop in cell viability. The cancer cells, deprived of their essential survival pathway, collapsed rapidly. The anticancer mechanism of selinexor, a representative SINE-class targeted drug, has also been elucidated in detail. ATRT cells treated with selinexor ceased proliferation, remained in the quiescent G0 phase, and entered a cascade of apoptotic pathways. Transcriptomic data provided clear numerical evidence supporting this cell death process. In the drug-treated group, the TP53 signaling pathway (a tumor suppressor pathway) and apoptosis-related genes showed a steep increase, while gene sets regulating the cell cycle were simultaneously depleted. The structure shows the TP53 protein, which was being exported from the nucleus, becoming trapped inside and inducing tumor apoptosis. Significance and Outlook This achievement is significant because it demonstrates that XPO1 is a critical genetic dependency and a viable target supporting the survival of cells in ATRT, an intractable pediatric brain tumor. A breakthrough in identifying a new drug target in the field of rare pediatric cancers, where clear genetic drivers had remained elusive. Since selinexor has already received regulatory approval as a treatment for adult multiple myeloma, drug repurposing research is expected to gain momentum, significantly reducing development time and costs. Several validation steps remain before actual clinical implementation. It must be further confirmed in in vivo animal models whether the drug reaches sufficient concentrations at the tumor center by crossing the blood-brain barrier (BBB). A key challenge is meticulous dose design to ensure that vulnerable infant patients can tolerate drug side effects commonly seen in adult clinical trials, such as thrombocytopenia, nausea, and fatigue. Furthermore, exploring combination therapies to block mutations in the target binding site or drug resistance that may arise during long-term administration is an essential research task.
💡 The XPO1 inhibition strategy identified by the researchers directly leads to a customized combination therapy for pediatric patients under 3 years of age, who cannot undergo brain radiation. A representative application model is designing a clinical protocol that uses oral selinexor in combination with lower doses of standard anticancer chemotherapy. By mitigating systemic toxicity while maintaining anticancer efficacy through drug interactions, it can protect against brain developmental damage in pediatric patients. Expansion into low-dose long-term maintenance therapy to remove micro-residual tumors after surgery or prevent recurrence is also anticipated. This could lead to the establishment of a precision medicine system that selects and administers drugs to high-risk groups by measuring XPO1 expression levels in tumor tissue at the time of diagnosis.
Stem cells international🤖 AI summaryMesenchymal Stem Cell Exosomes Break the Inflammatory Chain of Dry Eye Disease via Multi-Immune Modulation and Ubiquitin Pathways
Background Dry eye disease (DED) is not merely a simple lack of tears, but a chronic inflammatory disease characterized by the destruction of the tear film, corneal damage, and the collapse of immune balance. Patients suffer from severe ocular pain, foreign body sensations, and blurred vision, experiencing profound fatigue in their daily lives. The prevalence is rising sharply due to increased use of electronic devices and an aging population. However, existing clinical responses have been limited to artificial tears, steroids, or immunosuppressants. These symptomatic therapies were insufficient to fundamentally block the inflammatory cascade occurring sequentially on the ocular surface. In particular, long-term steroid use carries the risk of side effects such as increased intraocular pressure or cataract formation. Immunosuppressants have also been identified as causes of low patient compliance due to severe burning sensations upon instillation and the months required for therapeutic effects to manifest. This has created an urgent need for new bioactive substances that can normalize the ocular surface microenvironment and induce damaged tissue regeneration. Key Findings Mesenchymal stem cell-derived exosomes (MSC-Exos) are considered next-generation therapeutic materials due to their inherently low immunogenicity and tissue regeneration capabilities. A recently published mechanistic analysis study specifically demonstrated that MSC-Exos suppress ocular surface inflammation by simultaneously controlling multiple complex signaling pathways. The most prominent effect is observed in the comprehensive blockade of inflammatory signaling pathways. The structure strongly inhibits the Toll-like receptor 4 and nuclear factor kappa B (TLR4/NF-κB) signaling axis, which triggers inflammatory responses on the cell surface, while simultaneously blocking the downstream IRAK1/TRAF6/NF-κB cascade. The STAT3 transcriptional regulatory network, which induces inflammatory cytokine production, is also a target of inhibition. The activation pathway of the NLRP3 inflammasome, a key mediator of cell damage and inflammation amplification, was also blocked. Mechanisms for restoring the balance of immune cells on the lacrimal gland and corneal surface were also revealed. Researchers explain that MSC-Exos produce a synergistic effect by correcting the balance between helper T cells 17 (Th17) and regulatory T cells (Treg) via the gut-eye axis. This method reduces overly aggressive Th17 cells and promotes the proliferation of immune-suppressing Treg cells. Additionally, a mechanism that promotes the FBXW7-mediated ubiquitination pathway, which is a regulator of protein degradation, contributes to accelerating the degradation of inflammatory mediator proteins. In essence, the improvement of the local microenvironment and systemic immune regulation pathways work together organically. Significance and Outlook These research results provide clear molecular biological coordinates for the development of next-generation biotherapeutics targeting ocular surface diseases. Unlike existing synthetic drugs that are limited to single receptor blockade, exosomes, as intercellular messengers, organically control multiple signaling networks. If formulated as eye drops or biomaterial composites, they are expected to become a practical therapeutic alternative for severe patient groups unresponsive to existing immunosuppressive therapies. There are significant engineering and clinical barriers to overcome before commercialization. Overcoming the inherent heterogeneity of exosomes, where the composition of secreted substances varies depending on cell origin and culture conditions, is a primary task. Standardization of separation and purification processes must follow to maintain uniform quality during mass production. Due to the nature of the eye, where drugs are rapidly washed away by blinking and tear circulation, increasing drug delivery efficiency and in vivo persistence is also a difficult challenge. Researchers point to the convergence of nanotechnology and gene-editing technology as the solution. When engineered exosomes, with amplified therapeutic functions through surface modification or genetic engineering, are developed, the era of precision biologics for dry eye disease is expected to officially begin.
💡 In clinical ophthalmology, the treatment protocol for dry eye disease will shift from short-term symptom relief to the fundamental reconstruction of the immune microenvironment. Patients who had previously relied on frequent artificial tear instillation or endured the burning sensation associated with immunosuppressant therapy can reduce their treatment burden through high-efficiency exosome eye drop therapy. This marks a direct turning point for preserving vision and improving the quality of life in severe patients at risk of chronic corneal damage and ulcers. For the pharmaceutical and biotech industries, this provides a technological turning point to standardize the previously vague efficacy of stem cell therapies into precise data at the nanovesicle level. In particular, joint development is expected to become more active with companies that possess nano-carrier synthesis technology or cell-line gene-editing platforms. The exosome pipeline for dry eye disease treatment has a high potential to expand its indications to ocular surface complications resulting from Sjögren's syndrome or graft-versus-host disease.
Journal of physiology and biochemistry🤖 AI summaryDismantling the Immunosuppressive Barrier of the Pancreatic Cancer Microenvironment via lncRNA to Induce Macrophage Reprogramming
Background Pancreatic ductal adenocarcinoma (PDAC) is a fatal, intractable malignant tumor with a 5-year survival rate of less than 12% after diagnosis. Even immunotherapy, which has become a mainstay of modern anticancer treatment, struggles against pancreatic cancer because the complex and robust tumor microenvironment (TME) surrounding the tumor forms a powerful immunosuppressive barrier. The immune cell that occupies the most overwhelming proportion within this microenvironment is known as tumor-associated macrophages (TAM). While macrophages in a normal state attack external invaders or mutated cells, in the pancreatic cancer environment, they are tamed by signals emitted from cancer cells and undergo polarization to an M2 phenotype. Macrophages transformed into the M2 phenotype promote cancer cell metastasis and invasion while blocking the access of cytotoxic T cells. They essentially act as key facilitators in enhancing treatment resistance. To inhibit tumor growth, it is necessary to reverse M2-TAM polarization and restore anti-cancer immunity; however, it has been difficult to clearly identify precise regulatory molecules that alter the properties of macrophages. Key Findings Recently, researchers comprehensively identified that long non-coding RNA (lncRNA), a type of non-coding RNA, is a key factor coordinating macrophage polarization within the pancreatic cancer microenvironment. Known as transcripts that do not directly produce proteins, lncRNAs induce M2 polarization across three dimensions: transcriptional regulation, epigenetic modification, and post-transcriptional control. Specifically, lncRNAs recruit chromatin remodeling enzymes to change gene expression patterns or activate competitive endogenous RNA (ceRNA) networks to protect transcription factors necessary for M2 differentiation. They act as sponges that absorb microRNA (miRNA), preventing the degradation of proteins that induce M2 signaling. Mechanisms where they directly activate major intracellular signaling pathways, such as STAT3 or NF-κB, to amplify the secretion of immunosuppressive cytokines have also been confirmed. Accordingly, a therapeutic strategy to reprogram the tumor microenvironment by controlling abnormally activated lncRNAs has been proposed. Representative methods include targeted knockdown using small interfering RNA (siRNA), genome editing based on CRISPR gene scissors, and antisense oligonucleotide (ASO) treatment. By combining small-molecule compounds that block lncRNA downstream signaling pathways with nanoparticle-based delivery vehicles, it is possible to accurately deliver RNA therapeutics, which are prone to degradation, to tumor-associated macrophages (TAMs) within tumor tissue, thereby repolarizing the M2 phenotype into an anti-tumor M1 phenotype. Significance and Outlook This review is noteworthy for presenting the possibility of reconstructing the previously impenetrable immunosuppressive environment of pancreatic cancer at the molecular level. A strategy to convert macrophages into the tumor-attacking M1 type, rather than simply removing them, is evaluated as a powerful alternative that can maximize the synergistic effects with existing immune checkpoint inhibitors. Furthermore, analyzing lncRNA expression patterns associated with M2 polarization can serve as a biomarker for precisely predicting patient prognosis and designing optimal treatment pathways. Challenges also remain. lncRNAs have complex secondary structures and low target delivery efficiency within tumor tissue, making it difficult to ensure safety upon administration in humans. The validation of highly efficient targeted nano-platforms capable of delivering drugs deep into pancreatic tumors while minimizing potential off-target side effects on normal immune cells is expected to be the watershed for future clinical translation.
💡 The lncRNA-based macrophage repolarization strategy can be implemented as a combination therapy pipeline combined with standard pancreatic cancer chemotherapy or immune checkpoint inhibitors. A realistic application model is the development of companion diagnostic kits that predict the ratio of aggressive M2-TAMs by measuring specific lncRNA expression levels in patient biopsy tissues using digital PCR or RNA sequencing. By administering targeted antisense oligonucleotides (ASOs) loaded into lipid nanoparticles (LNPs) to penetrate the tumor stromal barrier and reprogram tumor-associated macrophages (TAMs), this approach can directly contribute to the development of next-generation cell-targeted therapeutics that convert pancreatic cancer from a "cold" to an immunologically "hot" tumor state with activated immune responses.
Frontiers in pharmacology🤖 AI summaryLipid Metabolism Regulating Enzyme PPAP2C Identified as Key Factor Driving Aggressiveness and Poor Prognosis in Refractory Breast Cancer
Background Breast cancer is a leading cause of cancer-related mortality among women worldwide and exhibits high heterogeneity according to molecular subtypes. Advances in precision therapy tailored to the presence or absence of hormone receptor and human epidermal growth factor receptor 2 (HER2) expression. However, triple-negative breast cancer (TNBC) with all three receptors deficient still has limited targeted therapy options. Many patients experience early recurrence after chemotherapy and face refractory states. There is an urgent need to identify novel targets to improve survival rates for this subtype. Recently, the oncology community has been focusing on the abnormal lipid metabolism reprogramming of cancer cells. Malignant tumors disrupt phospholipid metabolism to activate survival signals for rapid proliferation. This is the background for the growing interest in the role of the Phospholipid Phosphatase (PLPP) family, which mediates metabolic regulation. In particular, the function of Phosphatidic Acid Phosphatase Type 2C (PPAP2C) remained unclear. This was a time when there was an urgent need to identify metabolic vulnerabilities. Key Findings The researchers performed an integrated analysis of The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) database, and the Cancer Cell Line Encyclopedia (CCLE). A comparison across 33 cancer types revealed that PPAP2C expression increased in 16 types and decreased in only 3. This represents the most pronounced overexpression pattern among all cancer types. Expression levels surged in breast cancer tissues compared to normal tissues, and the intensity of expression increased proportionally as the disease stage progressed. Molecular subtype analysis showed concentrated expression increases in HER2-positive and TNBC, which have poor prognoses. The researchers verified survival correlations using TCGA, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Gene Expression Omnibus (GEO) cohorts. The high-PPAP2C group showed unfavorable results in both overall survival and recurrence-free survival compared to the low-expression group. Its value as an independent prognostic factor was confirmed via multivariate Cox analysis. Using Immunohistochemistry (IHC) on Tissue Microarray (TMA) specimens, they confirmed the same trend of worsening prognosis at the protein level. To reveal protein function, cellular-level functional evaluations were conducted. Using CRISPR-Cas9 technology on highly aggressive TNBC cell lines, researchers established knockout and overexpression models. Cancer cells with blocked PPAP2C expression showed slowed proliferation rates and reduced colony formation. Cell motility and invasive capacity significantly decreased compared to the control group. Conversely, under conditions of gene overexpression, cancer cell motility and invasiveness increased dramatically. This provides experimental evidence that this enzyme acts as a functional driver regulating the malignant phenotype of breast cancer. Significance and Outlook This study suggests that a specific enzyme in lipid metabolism functions as a key molecular switch determining breast cancer malignancy. To date, breast cancer targeted therapy has been largely focused on protein kinase inhibitors or hormone blockers. The discovery of a new target that directly regulates lipid metabolites expands the therapeutic landscape for refractory breast cancer. The alignment between protein-level verification using patient specimens and big-data cohort analysis supports the potential for future clinical application as a biomarker. The immediate challenges that follow-up research must address are also clear. Since the aggressive phenotype was verified in cell line models, additional verification in animal experiments and organoid models is required. Analysis must also follow to identify which downstream metabolite pathways trigger tumor growth during the dephosphorylation of phosphatidic acid by PPAP2C. The fact that a dedicated inhibitor has not yet been developed is also identified as a barrier to overcome. If the synthesis of inhibitors that precisely target the enzyme's active site accelerates, it is expected to emerge as a promising pipeline to fill the therapeutic gap.
💡 This research can generate direct industrial impact along two key axes: the early screening of patients with aggressive breast cancer and the development of customized therapeutics. This includes the potential commercialization of Companion Diagnostic (CDx) kits that measure PPAP2C protein expression levels via IHC in pre-surgical biopsy or resected specimens. By using it as an auxiliary prognostic tool for patient groups in whom high-risk identification via existing receptor diagnostics is difficult, it becomes possible to establish protocols for providing preemptive treatment to patients expected to experience aggressive metastasis. In terms of the drug development pipeline, this directly leads to targets for new drug discovery using small molecule compounds or Proteolysis-Targeting Chimera (PROTAC) technology. Refining clinical strategies for patients with metastatic triple-negative breast cancer who have no adequate standard treatment alternatives. Representative approaches include administering PPAP2C inhibitors alone or in combination with immunotherapy to block lipid metabolism signals. The mechanism of inhibiting cancer cell metastasis and proliferation is expected to offer a viable therapeutic alternative for refractory patients who have developed resistance to conventional chemotherapy.
FEMS microbiology reviews🤖 AI summaryIdentification of Molecular Mechanisms of Extracellular Vesicle-Mediated HIV Latency and Immune Disruption, and Expansion into Therapeutic Platforms
Background Human Immunodefirus Virus (HIV) infection has transitioned into a manageable chronic disease following the introduction of potent Antiretroviral Therapy (ART). However, the fundamental reason why a cure is not achieved, even when viral loads are reduced below the limit of detection, lies in the latent viral reservoirs within the body and continuous chronic immune dysfunction. This is why proviruses hidden in resting memory CD4+ T cells begin to proliferate again upon discontinuation of medication. Even when viral replication is suppressed, systemic inflammation and immune system disruption persist. The academic community has focused on extracellular vesicles (EVs), which act as intercellular signaling mediators, as the underlying cause of these pathological phenomena. As lipid bilayer nano-particles secreted by cells, EVs serve as key mediators for transferring proteins, lipids, and nucleic acids from parent cells to surrounding cells. Existing virological research has focused primarily on direct contact between free virus particles and target cells, but the complex functions of EVs exchanged between infected and uninfected cells have not been sufficiently elucidated. There is a growing call to comprehensively elucidate the molecular mechanisms of EVs at the interface between viral and host cell pathways, which is essential for achieving breakthroughs in reservoir clearance and alleviating chronic inflammation. Key Findings This study systematically identifies the molecular mechanisms through which EVs intervene in host-virus interaction, immune regulation, chronic inflammation, and the maintenance of viral latency during the HIV infection process. EVs released from infected cells exhibit opposing or complex actions depending on their cell of origin and loaded cargo. EVs carrying viral proteins such as Nef or Tat, and non-coding RNA fragments like TAR, move to uninfected immune cells, showing patterns of inducing cell death or promoting immune activation. Conversely, evidence was also found that they help the infectious agent evade immune surveillance by suppressing antiviral immune responses. EVs also act as a key link in maintaining the viral latency reservoir. The EV cargo in the microenvironment surrounding latently infected cells performs functions such as delivering transcriptional repression signals to solidify latency or interfering with latency reversal signals to neutralize immune cell detection. The study explains that even in patients on ART with suppressed viral replication, EVs carrying pathogenic cargo are continuously secreted, inducing chronic inflammation and immune exhaustion. Furthermore, therapeutic strategies that exploit EV biology were extensively discussed. The starting point is a method to delay disease progression by blocking the biogenesis and secretion of pathogenic EVs using sphingomyelinase inhibitors, etc. Using highly biocompatible engineered EVs as drug delivery vehicles is also a promising approach. Customized EVs loaded with CRISPR gene scissors, latency reversal agents, or antivirals are considered next-generation platforms for targeted correction of the reservoir genome or deep delivery of drugs within the body. However, the incomplete separation of damaged virus particles and EVs, and the high heterogeneity between vesicles, were pointed out as limitations to be wary of during data interpretation. Significance and Outlook This review provides an opportunity to expand the scope of HIV treatment research from simple viral suppression to the control of intercellular communication networks. Targeted delivery technology using engineered EVs is considered a viable alternative to overcome the immunogenicity and Blood-Brain Barrier (BBB) permeability limitations faced by synthetic nanoparticles. It has opened up a biocompatible means to deliver precise therapeutic substances to deep-seated reservoirs, such as the central nervous system. Barriers remain to be resolved before actual clinical implementation. The establishment of standardized protocols for selectively isolating and quantifying HIV-specific pathogenic EVs among the countless vesicles in body fluids must come first. Establishing mass production processes for therapeutic EVs and suppressing side effects caused by uptake by non-target cells are also challenges to be addressed. If these foundational technologies mature, EV control technology is expected to serve as a decisive foothold toward a cure when combined with strategies to awaken and eliminate latent viruses.
💡 From the perspective of clinical practice and the pharmaceutical industry, this study presents two specific application pathways. First, it is possible to develop companion diagnostic biomarkers for the non-invasive evaluation of the residual size of latent reservoirs and systemic chronic inflammation status by precisely analyzing viral proteins and microRNAs carried in circulating extracellular vesicles (EVs) within blood or cerebrospinal fluid. In terms of therapeutic development, a realistic alternative is emerging to design customized drug delivery vehicles by loading gene scissors for cleaving integrated viral genes or latency-reversing agents into patient-derived dendritic cell- or stem cell-derived EVs to target latent reservoirs residing deep within the central nervous system and lymphoid tissues. This directly leads to a next-generation therapeutic platform that avoids the liver toxicity induced by existing synthetic Lipid Nanoparticles (LNPs) and dramatically increases targeted delivery efficiency.
Blood science (Baltimore, Md.)🤖 AI summaryCell membrane phospholipid remodeling enzyme LPCAT3 emerges as a metabolic target driving acute myeloid leukemia progression
Background Acute myeloid leukemia (AML) is a fatal malignancy where immature myeloid progenitors proliferate abnormally, paralyzing normal hematopoietic functions. Due to varying genetic mutations and molecular biological characteristics among patients, high recurrence rates and resistance frequently occur even with conventional chemotherapy or targeted therapies. The oncology community is focusing on the disruption of cellular homeostasis that sustains cancer cell division and survival. Proliferating leukemia cells appear to actively remodel lipid metabolism to maintain physical membrane structures and transmit growth signals. The Lands' cycle, a remodeling pathway for phospholipids—key lipids in the cell membrane—is an essential biochemical process regulating membrane fluidity and cellular functions. However, it has not been clearly elucidated how metabolic enzymes involved in the Lands' cycle specifically act on AML progression and leukemia cell viability. As existing targeted therapy strategies encounter acquired resistance, there is an urgent need to identify fundamental vulnerabilities in leukemia cell membrane metabolism. Key Findings Researchers have identified lysophosphatidylcholine acyltransferase 3 (LPCAT3), a key enzyme in the Lands' cycle, as a major factor driving the malignant progression of AML. Analysis of large-scale public transcriptomic data and patient-derived CD34-positive (CD34+) cells revealed that LPCAT3 expression levels are significantly elevated in patient tissues compared to normal cell groups. It was confirmed that patient groups with high LPCAT3 expression levels have significantly poorer overall survival than those with low levels. Similar trends were captured in experiments using representative AML models, the MOLM-13 and THP-1 cell lines. Inhibiting LPCAT3 using gene silencing via short hairpin RNA (shRNA) and CRISPR-Cas9 knockout technology resulted in slowed cell proliferation. Cell cycle analysis showed induced G0/G1 phase arrest, and the rate of apoptosis significantly increased. Xenograft mouse models injected with LPCAT3-deficient cells also showed a noticeably reduced leukemic burden in vivo compared to the control group. RNA sequencing (RNA-seq) analysis provided crucial clues for identifying the detailed mechanism. In cells where LPCAT3 was inhibited, differentially expressed genes (DEGs) were concentrated in pathways related to granulocyte chemotaxis. This implies that the loss of metabolic enzymes changed the transcriptomic landscape in a direction that relieves the inhibition of leukemia cell differentiation and normalizes interactions with the microenvironment. Significance and Outlook This study is significant in that it proves LPCAT3, a cell membrane lipid metabolism enzyme, as a new target for AML, moving beyond the gene mutation-centered approach. It demonstrates the effectiveness of a metabolic therapeutic approach that disrupts the physical stability of cancer cells by manipulating cell membrane phospholipid composition. Follow-up studies investigating the connection with the regulation of polyunsaturated fatty acid oxidation or ferroptosis (iron-dependent cell death) are also expected to gain momentum. Challenges remain for actual clinical application. LPCAT3 is considered an essential enzyme involved in lipid absorption and lipoprotein synthesis in normal organs as well. It is pointed out that the risk of toxicity to normal cells and metabolic imbalance during systemic administration cannot be ruled out. Establishing a delivery system that precisely targets only leukemia cells while protecting normal hematopoietic stem cells is an essential task. Furthermore, analysis suggests that the discovery of clinical-grade small molecule compounds that selectively inhibit LPCAT3 must accompany this effort.
💡 The LPCAT3 targeting strategy may offer an alternative for the treatment of refractory AML patients who exhibit resistance to existing standard anticancer therapies. A representative scenario is designing a treatment protocol that co-administers LPCAT3 inhibitors to overcome secondary resistance appearing after the administration of FLT3 or IDH1/2 inhibitors. Another valid strategy is a combination therapy aimed at increasing the intracellular penetration efficiency of existing anticancer drugs or seeking synergistic effects with apoptosis inducers by artificially destabilizing the lipid composition of leukemia cell membranes. The LPCAT3 expression level confirmed in patient-derived CD34-positive cells is expected to be introduced into clinical practice as a companion diagnostic biomarker to assess a patient's initial risk group and treatment responsiveness.
International journal of pharmaceutics: X🤖 AI summaryFrom Bloodstream Degradation to Nuclear Entry: Overcoming Multi-stage Biological Barriers of CRISPR Gene Therapies via Nanoengineering
Background CRISPR-Cas9 gene-editing technology is considered a key means to treat incurable genetic diseases by correcting specific DNA sequences. However, in vivo applications—where gene-editing tools are injected directly into the body—have repeatedly faced physical and biological barriers. It is extremely difficult for editing complexes to safely reach the interior of target tissue cell nuclei after entering the body. Immediately after injection, they are exposed to indiscriminate attacks by extracellular degradation enzymes while circulating in the bloodstream and are prematurely cleared by the reticuloendothelial system, including macrophages. Even if they reach the target organ, cell membrane uptake rates are low, and most nanoparticles that enter the cell are destined to be degraded in lysosomes after being trapped in endosomal vesicles. Previously, viral vectors such as Adeno-associated virus (AAV) were primarily adopted as carriers. However, viral vectors have fatal weaknesses: high immunogenicity, limited gene loading capacity, and the risk of increased off-target cleavage of unintended sequences due to their long-term presence in the body. This is why academia and industry have shifted their focus toward non-viral nanoparticle engineering capable of stepwisely breaking through complex biological barriers. Key Findings The researchers systematically classified the biological barriers that CRISPR materials encounter in the body and established a 'barrier-oriented engineering' framework that precisely engineers nanoparticles according to the physicochemical properties of each stage. In the first hurdle, the blood circulation process, surface modification technology to extend residence time is key. PEGylation processes, which coat the nanoparticle surface with polyethylene glycol (PEG) polymers, or biomimetic coatings using red blood cell or platelet membranes were applied. This method inhibits the phenomenon where serum proteins adsorb onto the particle surface and lead to phagocytosis by macrophages, thereby securing a half-life within the bloodstream. In the second gate, the target tissue uptake stage, a method of binding cell-specific ligands was presented. The idea is to place peptides or antibody fragments that bind to receptors on the particle surface to induce entry into specific lesion cells while bypassing normal cells. In the third gate, the endosomal escape stage within the cytoplasm, smart release systems demonstrate their efficacy. Ionizable lipids and pH-responsive polymers were integrated to change shape and rupture endosomal membranes in the low-pH environment inside endosomes. Stimulus-responsive designs that release gene-editing materials in a timely manner in response to external signals or inherent biochemical characteristics of the lesion site, such as reactive oxygen species (ROS) concentrations or specific degradation enzymes, were also highlighted. In the final hurdle, the nuclear entry stage, strategies were identified to combine an optimized combination of nuclear localization signal (NLS) sequences with the Cas9 protein structure or to manipulate nanoparticles to utilize endogenous intracellular transport pathways. This principle maximizes nuclear membrane passage efficiency, thereby significantly boosting genome-level editing efficiency. Significance and Outlook It is assessed that an integrated engineering roadmap has been established, moving beyond previous research trends focused on addressing single barriers to encompass the entire process from systemic entry to nuclear localization. This is because for CRISPR delivery technology to transition from laboratory-scale cell culture to a viable in vivo therapeutic, multiple layered hurdles must be overcome simultaneously. Practical challenges to overcome for commercialization remain significant. As more diverse surface modifications and complex materials are introduced, the nanoparticle manufacturing process becomes more complex, making it difficult to maintain quality uniformity during mass production. Thorough verification is also required regarding potential toxicity caused by unintended accumulation in the liver or spleen during high-dose administration and the possibility of inducing immune responses in the body. In essence, an optimal balance must be found that satisfies both target accuracy and biocompatibility while increasing intracellular delivery efficiency. Researchers predict that artificial intelligence (AI)-based molecular modeling and machine learning algorithms will serve as breakthroughs for next-generation nanoparticle design. This is because they can rapidly screen structures exhibiting optimal delivery efficiency from tens of thousands of lipid compositions and surface peptide combinations in virtual space. Furthermore, if customized delivery technology reflecting the individual genetic and pathological characteristics of patients is combined with next-generation CRISPR variants that minimize off-target cleavage risks, the speed of clinical entry for treating incurable genetic diseases is expected to accelerate further.
💡 The barrier-oriented nanoengineering presented in this study could serve as a turning point to expand the application of gene-editing therapies, which have been concentrated on liver diseases, to systemic incurable diseases affecting the central nervous system, muscles, and lungs. Existing lipid nanoparticles mostly migrate to liver cells due to binding with Apolipoprotein E (ApoE) upon intravenous injection, making it difficult to target tissues other than the liver. By applying the ligand modification and biomimetic coating technologies developed in this study, it becomes feasible to penetrate the blood-brain barrier (BBB) to target and correct genes responsible for central nervous system genetic diseases such as Huntington's disease or spinal muscular atrophy. If engineered into an inhalation formulation for the respiratory system, gene-editing agents can be locally delivered to the lung epithelial cells of cystic fibrosis patients, thereby avoiding systemic toxicity and enhancing therapeutic efficacy. As reliance on viral vectors decreases, enabling repeated administration, it is expected to open new therapeutic pathways for patients with complex genetic diseases who could not achieve sufficient therapeutic effects with a single dose.
Reviews in medical virology🤖 AI summaryChallenges for Next-Generation Gene-Edited CAR-T Therapies Entering Clinical Trials to Target Viral Nasopharyngeal Carcinoma
Background Nasopharyngeal carcinoma (NPC), closely associated with the Epstein-Barr virus (EBV), is a difficult-to-treat solid tumor due to frequent recurrence and distant metastasis. Despite standard treatments such as concurrent chemoradiotherapy or immune checkpoint inhibitors, many patients in the metastatic stage fail to achieve sustained therapeutic responses. The biological characteristic of viral infection as a primary cause of development suggests the possibility of immunotherapy targeting virus-derived proteins. However, numerous obstacles remain before applying chimeric antigen receptor T-cell (CAR-T) therapy to NPC patients. A major barrier is the low surface exposure of viral latent antigens. Immune cells struggle to penetrate the tumor interior, and even if they do, T-cell exhaustion is rapidly induced by inhibitory signals within the tumor microenvironment. Antigen heterogeneity within the tumor cell population is also identified as a major cause of reduced sustained efficacy in cell therapies. Key Findings Recently, there have been active attempts in academia to overcome solid tumor resistance by fusing precision genome editing technologies, such as CRISPR-Cas9, with CAR-T. Researchers have systematically examined the potential of conventional gene scissors along with base editing, prime editing, and targeted gene insertion techniques that do not induce DNA double-strand breaks (DSBs). Representative design strategies include removing immunosuppressive receptors such as PD-1 or TGF-beta receptors, or engineering cells to secrete cytokines in an autocrine manner. The problem is the genotoxicity that follows the gene manipulation process. DNA double-strand breaks caused by the Cas9 protein pose risks of abnormal rearrangements such as chromosomal translocations, large deletions, and chromosome loss. Off-target cleavage and bystander mutations during the base editing process also remain factors threatening the safety of cell therapies. To date, early clinical successes of allogeneic CAR-T using base editing technology have been reported in the field of hematologic malignancies, but a gene-edited cell therapy platform validated in NPC patients is absent. Existing EBV-specific adoptive T-cell therapies or early clinical studies targeting NPC demonstrate the technical feasibility of genetic redesign but have not yet proven clinical efficacy in inducing actual solid tumor regression. Significance and Outlook For gene-edited CAR-T to take root in the treatment of nasopharyngeal carcinoma (NPC), the discovery and validation of new target antigens that are stably exposed on the cell surface must precede its implementation. It is also essential to select precision editing tools suitable for therapeutic purposes to avoid random cleavage and minimize genomic damage. A standard analytical framework must be established to monitor cumulative structural genomic abnormalities that arise when multiple sites are cleaved by a single gene editor, in order to cross the threshold for clinical approval. Furthermore, industrial challenges in ensuring consistency in mass production processes remain. Since patient-specific autologous cell therapies are prone to quality variations during manufacturing, the development of off-the-shelf allogeneic cell lines is emerging as an alternative. Future clinical trials are expected to be rigorously conducted from small-scale early stages, targeting patient groups selected via biomarkers such as tumor-specific antigen expression levels and immune microenvironment characteristics, rather than employing randomization.
💡 This review provides specific application guidelines for genome editing technology when designing personalized treatment strategies for metastatic NPC patients. For patients refractory to existing immune checkpoint inhibitors, a scenario can be envisioned in which treatment response rates are increased by combining multi-edited CAR-T cells that block immunosuppressive checkpoints. From the perspective of the biopharmaceutical industry, clear regulatory and development standards must be established regarding which genomic safety validation data should precede the expansion of the CAR-T market—currently focused on hematologic malignancies—into solid tumors.
Journal of the Egyptian National Cancer Institute🤖 AI summaryBacteriophage Vectors Emerge as Delivery Vehicles Targeting Liver Cancer Cells
Background Hepatocellular carcinoma (HCC) is a cancer with poor prognosis due to its molecular heterogeneity and frequent recurrence and drug resistance after treatment. It is estimated that approximately 850,000 new cases were diagnosed worldwide in 2024, with over 730,000 deaths. Although treatment options such as surgery, local therapy, immune checkpoint inhibitors, and targeted therapies have expanded, achieving sustained efficacy in advanced patients remains challenging. Gene therapy, which delivers therapeutic genes into tumor cells, is considered a promising alternative, but the delivery vector remains a major obstacle. Eukaryotic viral vectors such as adenovirus and adeno-associated virus (AAV) have high cell penetration capabilities but are limited by pre-existing immunity, non-target tissue exposure, and constraints in cargo capacity and production. Non-viral nanoparticles are relatively safer but often lack sufficient cellular uptake and gene expression efficiency. Bacteriophages, viruses that infect bacteria, are inherently non-infectious to mammalian cells but can be relatively easily modified in surface and genome structure. The research team reviewed prior studies on the application of phage-based vectors for targeted gene delivery to liver cancer and summarized the barriers to clinical translation. This paper is a narrative review that critically analyzes existing literature, not a new animal experiment or clinical trial. Key Findings The fundamental strategy proposed by the researchers is phage display. By expressing tumor-targeting peptides or antibody fragments on the surface coat proteins of phages such as M13, T4, T7, and lambda phage, the phages can be designed to selectively recognize receptors on liver cancer cells, such as glypican-3 (GPC3) and integrin. Candidates include the GPC3-targeting L5 peptide and integrin-binding arginine-glycine-aspartic acid (RGD) ligands. After phage entry via receptor-mediated endocytosis, the process of endosomal escape, cytoplasmic cargo release, nuclear translocation, and therapeutic gene expression must occur sequentially. In this context, AAVP vectors, which combine phage and AAV elements, have attracted attention. These vectors incorporate a mammalian expression cassette between AAV2 inverted terminal repeats and display tumor-targeting ligands on the phage coat. A representative cargo is the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Recombinant TRAIL protein has a short half-life in the bloodstream and low tumor accumulation, but delivering the TRAIL gene into liver cancer cells allows for intracellular TRAIL production. Expressed TRAIL activates death receptors and caspase-8, triggering downstream executioner caspases and mitochondrial pathways to induce apoptosis. In the reviewed cell culture studies, no TRAIL gene delivery was observed in normal liver cells. The concept of loading CRISPR-Cas9 to cleave or correct mutant oncogenes was also discussed. Single-guide RNA recognizes a 20-nucleotide target sequence, and Cas9 cuts double-stranded DNA three nucleotides upstream of the protospacer adjacent motif (PAM). However, the phage-CRISPR combination remains at an early developmental stage and is not yet a clinically validated therapeutic technology for liver cancer. Implications and Outlook Bacteriophages offer the advantage of combining targeting ligands and therapeutic cargo into a single particle and can be amplified through bacterial culture. Their lack of natural affinity for mammalian cells can also be a design element to reduce non-target delivery. The platform can be extended to integrate anti-cancer genes, gene-editing tools, and imaging agents, enabling combined diagnostic and therapeutic applications. However, surface binding does not necessarily equate to efficient gene expression. Phages are prone to degradation in endosomes and lysosomes, and the mechanisms for cytoplasmic escape remain insufficiently understood. After intravenous administration, the mononuclear phagocyte system in the liver and spleen rapidly clears the particles, and neutralizing antibodies may develop with repeated administration. Strategies such as polyethylene glycol conjugation or lipid vesicle encapsulation are potential candidates to prolong in vivo retention, but the balance between tumor binding and immune evasion must be validated. At the large-scale production stage, removal of bacterial endotoxins and residual DNA, as well as particle purity, titer, and stability, must be managed. Standardized good manufacturing practice (GMP) processes and regulatory frameworks are still under development. In particular, since this review does not provide independent efficacy data, preclinical validation of biodistribution, toxicity, and repeated administration effects in liver cancer organoids and immunocompetent animal models must be conducted first. The clinical potential of phage-based vectors can only be assessed after such preclinical evidence is accumulated.
💡 In practical development, a scenario could be considered in which patients with unresectable GPC3-positive hepatocellular carcinoma are selected, and TRAIL gene or tumor-dependent CRISPR cargo is loaded into phage-AAV hybrid vectors with GPC3-binding ligands and administered intravenously. Expressing therapeutic proteins only in tumor tissue could reduce normal liver damage and allow for combination with immune checkpoint inhibitors or transarterial chemoembolization. The first industrial challenge is to compare in vivo delivery rates rather than binding affinities of candidate ligands. Subsequently, endosomal escape rates, liver and spleen accumulation, neutralizing antibody formation, and endotoxin residue levels must be quantified and quality criteria established. The current value lies in consolidating the design principles and failure points of liver cancer-targeted gene delivery vectors rather than in an immediately applicable therapy. Journal of the Egyptian National Cancer Institute original article
Nature Genetics🤖 AI summaryCo-evolution of Subclonal Expansion and Metastatic Microenvironment in Lung Adenocarcinoma Captured by Spatial Lineage Tracing
Background Cancer progression is both a process of selecting genetically distinct cancer cell populations and an ecological change marked by the accumulation of hypoxia, immune suppression, and fibrosis. However, single-cell RNA sequencing disrupts tissue architecture, erasing the original spatial positions of cells, while multi-region sequencing often samples limited areas, missing the continuous spatial structure of cell states and lineages. It remains poorly understood where subclones grow, how they alter surrounding cells, and where metastasis-competent cells emerge within the primary tumor. To address these gaps, the researchers combined high-resolution spatial transcriptomics with lineage tracing that accumulates genetic barcodes over time. The model used was KP-Tracer mice, in which lung adenocarcinoma is induced by Kras activation and Trp53 deletion. Cre virus was administered to type 2 alveolar cells in 8–12-week-old mice to simultaneously initiate tumor development and CRISPR–Cas9 lineage recording. The design aimed to reconstruct not only the current transcriptional state of cancer cells but also their common ancestry and proliferation history within tissue coordinates. Key Findings The researchers used Slide-seq, which reads large tissue areas at subcellular resolution, and Slide-tags, which provide single-nucleus sensitivity. They analyzed over 100 tumors across 49 spatial transcriptomic arrays and applied a correction algorithm to recover missing lineage barcodes using spatial and genetic information from neighboring cancer cells. The median accuracy of restoring hidden barcodes in real data was 90%, and iterative correction recovered 4–58% (mean 31%) of missing information per dataset. The median accuracy of random predictions was 67%. As tumors progressed, cancer cells maintaining an alveolar state were mainly located at the periphery, while those with epithelial-mesenchymal transition (EMT) and hypoxia gene programs were found in the interior. Around rapidly expanding high-fitness subclones, Arg1-positive immunosuppressive tumor-associated macrophages and Postn-positive myofibroblast-like cancer-associated fibroblasts were enriched. Fitness calculated from lineage trees showed a Pearson correlation coefficient of 0.4 with existing transcriptome-based fitness metrics, and hypoxia–EMT spatial communities were most strongly associated with high fitness. This supports the sequential interplay of subclone proliferation, oxygen depletion, immune and stromal reprogramming, and metastasis-promoting cell states. Spatial analysis also identified an unreported cancer cell state expressing Piezo2, Robo1, and Pecam1, maintaining Nkx2-1 but not expressing Vim. In mice with widespread metastasis, the primary tumor was reconstructed in 3D by sectioning the lung every 200–500 micrometers. Metastatic lesions in mediastinal lymph nodes, ribs, and diaphragm were all lineage-linked to spatially restricted subclones within the primary tumor T2. The TGF-β program in metastatic lesions was nearly identical to that of the corresponding primary subclone (log2 fold change −0.14, P=1.0), but collagen-related expression was significantly increased (log2 fold change 3.81, P<10⁻⁵). COL3A1 protein staining further supported fibrosis in metastatic sites. Nature Genetics paper Implications and Outlook This study provides spatial evidence that aggressive cancer cell states are not fixed solely by internal mutations but are co-shaped by the hypoxic, immunosuppressive, and fibrotic environment created by subclone expansion. The finding that metastatic seeds are concentrated in specific local ecosystems rather than uniformly distributed throughout the primary tumor is also noteworthy. After metastasis, the existing TGF-β–EMT program is maintained, but collagen deposition is added, creating a new environment suitable for metastatic colonization. However, the results are largely dependent on the Kras;Trp53-based mouse lung adenocarcinoma model. Thin tissue sections may not fully represent the 3D structure of tumors, and the diversity of lineage barcodes in spatial data is lower than in dissociated single-cell analysis. The method of correcting missing barcodes using neighboring cells may introduce errors in highly mobile cancer cells. It remains to be verified whether the same spatial structure is reproducible in human lung adenocarcinoma cohorts and treatment-naïve specimens, and whether subclone metastatic potential is indeed reduced by blocking hypoxia or fibrosis signals.
💡 Clinically, this opens the possibility of adding a spatial risk map to the current practice of classifying surgical tissues based solely on genomic mutations. Identifying regions in histological sections where hypoxia–EMT cancer cells, Arg1-positive macrophages, and Postn-positive fibroblasts are in close proximity could serve as a basis for selecting high-metastasis-risk subclones and determining the intensity of adjuvant therapy. Pharmaceutical companies could evaluate combination therapies targeting TGF-β, hypoxia response, macrophage suppression, or collagen formation using organoid co-culture systems that mimic these regions. However, the current achievement is at the stage of proposing candidate ecosystems rather than proving clinical efficacy of therapeutic targets. Patient specimen prognosis linkage and prospective drug trials are still needed.
Molecular biomedicine🤖 AI summarymRNA Vaccine Binding Different RBDs Confirmed to Provide Cross-Protection Against Omicron Variants
Background Although vaccination against COVID-19 has reduced the risk of severe disease, the continuous diversification of SARS-CoV-2 Omicron lineages has rapidly diminished the effectiveness of infection prevention. In particular, amino acid variations in the receptor-binding domain (RBD) have become a key mechanism for evading binding by existing neutralizing antibodies. Even if vaccines are updated based on the antigen of one variant, the protective range may narrow again when new lineages emerge. Multivalent vaccines that mix antigens from multiple variants can address this issue, but differences in antigen expression levels and immunodominance may lead to responses skewed toward specific targets. The research team hypothesized that expressing two phylogenetically distant RBDs as a single immunogen could induce broader B cell and T cell responses. Based on this, they designed a heterodimeric mRNA vaccine 'SV' by serially linking an optimized monomeric RBD (BSCOV06) with the KP.3 variant RBD. Key Findings After two doses of SV in BALB/c mice, high-titer antibodies with neutralizing activity against BA.1, XBB.1.5, JN.1, KP.3, and the phylogenetically distant XDV variant were generated. Although the abstract did not provide absolute values for neutralizing titers per variant, the immunogenicity and cross-protective efficacy of SV were equal to or higher than those of three doses of BSCOV06, indicating a broader protective range with fewer doses. The research team went beyond neutralization assays and conducted integrated analyses of B cell receptor (BCR) and T cell receptor (TCR) repertoires. In the SV-vaccinated group, class-switched B cells showed increased somatic hypermutation, and naive B cell participation was sustained. T cell populations composed of multiple clones also expanded broadly, and both BCR and TCR showed significant reprogramming of VJ gene usage. This suggests that the dual RBD did not merely increase antibody quantity but fundamentally altered the composition of the adaptive immune response. Actual protective efficacy was evaluated in BALB/c and K18-hACE2 transgenic mice expressing human angiotensin-converting enzyme 2. When challenged with JN.1 or XDV virus, SV significantly reduced pulmonary viral loads and alleviated histopathological damage. The cross-reactivity of neutralizing antibodies and the expansion of lymphocyte repertoires translated into lung protection. Implications and Outlook These results suggest that placing two antigenically distinct RBDs into a single molecule could serve as a design strategy to counter the immune evasion of rapidly evolving viruses. Rather than simply mixing variant-specific vaccines, the concept involves using a single mRNA to co-express two antigens, enabling the immune system to recognize multiple epitopes simultaneously. This principle could also be evaluated for other viruses with frequent antigenic changes, such as influenza. However, the study was conducted in a preclinical mouse model. It remains to be confirmed whether the two RBDs are expressed at equivalent levels in humans and whether pre-existing immunity from prior infection or vaccination might bias the response toward specific variants. Future evaluations should also address the duration of protection, mucosal immunity, safety, and consistency of quality at manufacturing scale. Since the abstract did not disclose absolute neutralizing titers or statistical effect sizes, detailed data from the full paper and primate and clinical results will be necessary to assess the superiority of the candidate.
💡 If SV demonstrates efficacy in humans, it could shift vaccine development from a strategy of replacing one antigen per season to a universal booster approach that precombines phylogenetically distant lineages. Pharmaceutical companies may be able to adjust the breadth of protection by incorporating the RBD sequences of two variants into a single mRNA cassette without significantly altering the production process. Specifically, it may be worth exploring scenarios in which two doses provide immune protection equivalent to three doses in populations requiring repeated vaccinations, such as the elderly and immunocompromised individuals. However, to confirm this, clinical trials must compare infection and severe disease prevention rates, adverse reactions, immune durability, and response differences based on prior vaccination history.
British journal of pharmacology🤖 AI summaryExtracellular Vesicles Targeting Cancer Signaling Networks and Drug Delivery
Background Cancer cells do not grow solely through mutations. They continuously send signals to surrounding immune cells, fibroblasts, and endothelial cells to alter the tumor microenvironment in their favor. In this process, extracellular vesicles (EVs) have emerged as key transporters. These are nanometer-sized lipid membrane particles secreted by almost all cells, delivering biomolecules such as proteins, lipids, DNA, messenger RNA, and microRNA to other cells. Cancer-derived EVs regulate tumor initiation, growth, angiogenesis, immune evasion, and drug resistance. They can travel through the bloodstream to distant organs and preform the premetastatic niche. Conversely, EVs can be harnessed as therapeutic agents due to their biocompatibility and ability to enter cells, enabling targeted drug delivery to desired tissues. Their abundance in bodily fluids such as blood and urine, and their reflection of the molecular characteristics of the secreting cell, also make them attractive as liquid biopsy biomarkers. However, EVs vary in size, composition, and biogenesis pathways. Different subpopulations such as exosomes and microvesicles are separated and quantified using methods that differ across research institutions, making direct comparison of results difficult. This review organizes EV-based therapeutic research for six cancer types—breast, lung, colorectal, prostate, pancreatic, and glioblastoma—according to their physicochemical properties, engineering modifications, cargo, and mechanisms of action. Key Findings The therapeutic strategies proposed by the researchers are broadly divided into two approaches. First, blocking the production, release, or uptake of tumor-derived EVs to disrupt cancer cell communication. This approach may simultaneously weaken signals involved in metastasis, immune suppression, and treatment resistance, but it carries the risk of also interfering with EV functions in normal cells. The second strategy uses EVs themselves as drug delivery vehicles. Their lipid bilayer, similar to cell membranes, can encapsulate both hydrophilic nucleic acids and hydrophobic small-molecule drugs, protecting them from degradation in the body and facilitating their delivery into target cells. The review includes preclinical formulations carrying chemotherapeutic agents such as doxorubicin, paclitaxel, and gemcitabine, as well as small interfering RNA (siRNA), microRNA, and gene-editing tools. Attaching peptides, antibodies, or aptamers that recognize tumor receptors to the EV surface can enhance uptake by specific cancer cells. Clinical development is still in its early stages. Notable examples include a phase I trial delivering siRNA targeting the KRAS G12D mutation in mesenchymal stromal cell-derived EVs to pancreatic cancer patients, and phase I/II trials of engineered EVs carrying STING agonists to stimulate innate immune pathways. Approaches using dendritic cell-derived EVs as cancer vaccines have also been evaluated in lung cancer. However, this paper is a review that synthesizes various formulations and clinical cases, not a study presenting new animal experiments or patient efficacy data. The results should not be interpreted as definitive evidence of therapeutic effectiveness. Implications and Outlook EVs have a dual nature: they are both pathological signals spread by cancer and a biological platform for delivering therapeutics. Their ability to serve as both a target for disruption and a therapeutic delivery system distinguishes them from synthetic nanoparticles. In particular, EVs can cross biological barriers such as the blood-brain barrier relatively well, making them valuable in the development of glioblastoma treatments. The key to commercialization lies in large-scale production and quality control. The content of EVs can vary depending on the type and condition of the cultured cells, and protein aggregates or lipid particles may be introduced during the separation process. Even with the same particle count, the amount and biological activity of the effective cargo may differ, making dosage setting non-trivial. Common standards for cell sources, purity, efficacy testing, and storage stability, as well as long-term toxicity data, must be established. It must also be confirmed that EVs with enhanced tumor tropism do not accumulate in unexpected organs or carry tumor-promoting signals. In the near term, ensuring manufacturing consistency, safety, and actual drug delivery in early-phase clinical trials remains a core challenge.
💡 In the clinic, EVs can be developed as both therapeutic agents and companion diagnostics. For example, continuous measurement of mutant RNA or immune-suppressive proteins in tumor-derived EVs in the blood can track drug response and resistance emergence, while siRNA or chemotherapeutic agents tailored to a patient's molecular targets can be delivered via engineered EVs. In pancreatic cancer, EVs could serve as delivery vehicles for KRAS-targeting nucleic acids, and in glioblastoma, they could overcome the blood-brain barrier to deliver drugs. For pharmaceutical companies, establishing standardized production processes—from cell line development to culture, purification, and loading—and efficacy testing methods are top priorities. Clinical benefits will only be confirmed when comparative trials demonstrate that EV-based therapies achieve higher drug concentrations in tumors and lower systemic toxicity than existing treatments.
Blood🤖 AI summaryElucidation of the CD38 Metabolic Circuit in Pediatric T-ALL Suggests a Combination Strategy with Daratumumab
Background T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by the abnormal proliferation of immature T-cells. Although initial treatment outcomes for pediatric patients have improved, options remain limited and prognosis remains poor for refractory or relapsed cases. In particular, T-ALL exhibits diverse genomic and immunophenotypic profiles, making it difficult to achieve sustained responses with single-target therapies. CD38, a type II transmembrane glycoprotein, is expressed on the surface of T-ALL cells and is a target of the anti-CD38 antibody daratumumab, used in the treatment of multiple myeloma. Clinical trials are underway to apply CD38-targeted immunotherapy in both initial and relapsed T-ALL. However, whether CD38 functions merely as a surface marker or as a functional regulator of metabolism and signaling in leukemic cells has not been systematically elucidated. The impact of intratumoral CD38 expression variation on treatment response and relapse remains an unresolved challenge. Key Findings The research team applied multimodal profiling combining transcriptomic, proteomic, and metabolomic analyses to pediatric T-ALL specimens. Bulk RNA sequencing of 1,335 primary tumors revealed that CD38 expression varies across genomic and immunophenotypic subtypes. In contrast, flow cytometry of 150 primary samples and CITE-sequencing of 40 cases demonstrated broad surface expression of CD38 across multiple subtypes. While expression intensity varied, a significant proportion of patients showed potential as candidates for CD38-targeted therapy. A transcription factor CRISPR-screen identified RUNX1, RUNX3, and TP53 as candidate regulators that increase CD38 expression. Metabolomic profiling of CD38-perturbed cell lines revealed disruption of the polyamine metabolic pathway, which is involved in cell growth and survival. Based on these findings, the researchers combined CD38 targeting with difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, and observed extended survival in preclinical models compared to monotherapy. Another key connection was inflammatory and SRC family kinase signaling. Transcriptomic data from primary tumors, cell lines, and patient-derived xenograft (PDX) models consistently showed reduced interleukin-32 (IL32) expression when CD38 was absent or negative, supporting a functional link between CD38 and inflammatory signaling. In most genomic subtypes, CD38 expression was positively correlated with lymphocyte-specific protein tyrosine kinase (LCK). Daratumumab treatment increased LCK phosphorylation in cell lines, and combination therapy with dasatinib, an SRC family kinase inhibitor, improved preclinical survival outcomes compared to monotherapy. Implications and Prospects This study reinterprets CD38 not merely as a surface antigen recognized by antibodies, but as a functional hub where metabolic, inflammatory, and kinase signaling pathways intersect. The observation that LCK signaling is activated following daratumumab treatment suggests a potential adaptive survival pathway in leukemic cells in response to CD38 targeting. Blocking this pathway with dasatinib or inhibiting polyamine synthesis with DFMO may enhance the depth and duration of anti-CD38 therapy. However, the demonstrated efficacy is based on cell line and preclinical model data. Whether the survival benefits of combination therapy are reproducible in pediatric patients must be confirmed through clinical trials. Variability in CD38 expression across subtypes, antigen loss during treatment, and potential damage to normal immune cells are important variables to consider. There is also a possibility of overlapping immunosuppressive and hematologic toxicities between dasatinib and daratumumab, and pharmacokinetic/pharmacodynamic studies are required to determine appropriate dosing and administration sequences for DFMO combination. Future development of a biomarker system that simultaneously measures CD38, LCK phosphorylation, IL32, and polyamine metabolic status could help identify patients suitable for combination therapy.
💡 Clinically, this could lead to a strategy in which CD38 expression in leukemic cells of pediatric patients with relapsed or refractory T-ALL is confirmed, and combination therapies are selected based on LCK activity or polyamine metabolic features. For example, dasatinib could be added to patients showing increased LCK phosphorylation after daratumumab treatment, and DFMO could be combined for tumors with high polyamine dependency. From an industrial perspective, this opens opportunities for drug repositioning by developing new combinations of drugs with existing clinical experience. However, before actual development, pediatric-appropriate dosing, administration sequence, cumulative toxicity, and recovery of normal T-cells must be evaluated. Parallel development of functional metabolic and signaling biomarkers as companion diagnostics, rather than relying solely on CD38 expression for patient selection, is also necessary.